Emyria Beheer

Beheer criteriumcontroles 4/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Michael Winlo

Algemeen directeur

AU$542.1k

Totale compensatie

Percentage CEO-salaris	70.1%
Dienstverband CEO	5yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	5yrs
Gemiddelde ambtstermijn bestuur	3.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Michael Winlo's beloning veranderd ten opzichte van Emyria's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$542k	AU$380k	-AU$11m
Mar 31 2024	n/a	n/a	-AU$12m
Dec 31 2023	n/a	n/a	-AU$12m
Sep 30 2023	n/a	n/a	-AU$9m
Jun 30 2023	AU$620k	AU$380k	-AU$5m
Mar 31 2023	n/a	n/a	-AU$6m
Dec 31 2022	n/a	n/a	-AU$8m
Sep 30 2022	n/a	n/a	-AU$7m
Jun 30 2022	AU$615k	AU$486k	-AU$7m
Mar 31 2022	n/a	n/a	-AU$7m
Dec 31 2021	n/a	n/a	-AU$6m
Sep 30 2021	n/a	n/a	-AU$6m
Jun 30 2021	AU$471k	AU$350k	-AU$5m
Mar 31 2021	n/a	n/a	-AU$5m
Dec 31 2020	n/a	n/a	-AU$5m
Sep 30 2020	n/a	n/a	-AU$5m
Jun 30 2020	AU$506k	AU$362k	-AU$5m

Compensatie versus markt: De totale vergoeding ($USD 352.27K ) Michael } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 297.98K ).

Compensatie versus inkomsten: De vergoeding van Michael is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Michael Winlo

5yrs

Tenure

AU$542,066

Compensatie

Dr. Michael Winlo serves as Managing Director of Emyria Limited (formerly known as Emerald Clinics Limited) since November 26, 2019 and served as its Chief Executive Officer until November 26, 2019. Dr. Wi...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Winlo	MD & Director	5yrs	AU$542.07k	0.25% A$ 40.8k
Alistair Vickery	Executive Medical Director & Director	5.7yrs	AU$485.37k	geen gegevens
Joseph Ohayon	Chief Financial Officer	no data	geen gegevens	geen gegevens
Tracie Ernenwein	Head of Research & Drug Development	no data	geen gegevens	geen gegevens
Mary-Ann Rennie	Head of Corporate Operations	no data	geen gegevens	geen gegevens
Susan Park	Company Secretary	1.7yrs	geen gegevens	geen gegevens

5.0yrs

Gemiddelde duur

Ervaren management: Het managementteam van EMD is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Winlo	MD & Director	5yrs	AU$542.07k	0.25% A$ 40.8k
Alistair Vickery	Executive Medical Director & Director	5yrs	AU$485.37k	geen gegevens
Henry Bosch	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Gregory Hutchinson	Independent Non-Executive Chairman	less than a year	AU$85.64k	1.56% A$ 253.5k
John Tooke	Member of Medical Advisory Board & Independent Non-Executive Director	4.8yrs	AU$50.00k	geen gegevens
Mohit Kaushal	Non-Executive Director	1.3yrs	AU$180.54k	geen gegevens
Karen Smith	Non-Executive Director & Chairman of Strategic Advisory Board	3.8yrs	AU$116.31k	0.15% A$ 24.7k
David Putrino	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Nik Zeps	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Philip Finch	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Jennifer Morgan	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Richard Magtengaard	Member of Medical Advisory Board	3.8yrs	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van EMD wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Emyria Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Emyria Limited, Annual General Meeting, Nov 12, 2024

Emyria Limited Appoints Greg Hutchinson as Director

Emyria Limited Announces Board Changes

Emyria Limited, Annual General Meeting, Nov 16, 2023

Emyria Limited Announces Strategic Board Transition

Less than half of directors are independent

Recent updates

New major risk - Share price stability

Emyria Limited, Annual General Meeting, Nov 12, 2024

Full year 2024 earnings released: AU$0.032 loss per share (vs AU$0.018 loss in FY 2023)

New minor risk - Share price stability

New major risk - Market cap size

Emyria Limited has filed a Follow-on Equity Offering in the amount of AUD 2.3 million.

New major risk - Financial position

Emyria Limited Appoints Greg Hutchinson as Director

Emyria Limited Announces Board Changes

Emyria Limited has completed a Follow-on Equity Offering in the amount of AUD 1.678228 million.

Emyria Limited (ASX:EMD) completed the acquisition of The Pax Centre from Glenroyale Pty Ltd and Vivo (WA) Pty Ltd.

Emyria Limited (ASX:EMD) completed the acquisition of The Pax Centre from Glenroyale Pty Ltd and Vivo (WA) Pty Ltd.

Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.027 loss in FY 2022)

Emyria Limited, Annual General Meeting, Nov 16, 2023

New minor risk - Financial data availability

Emyria Limited Announces Strategic Board Transition

New minor risk - Share price stability

Emyria Limited (ASX:EMD) signed an agreement to acquire The Pax Centre from Glenroyale Pty Ltd for AUD 1.7 million.

Emyria Limited Secures Clinical-Grade MDMA Supply for Aust Patients

Emyria Limited Expands MDMA Programs Following Landmark TGA Decision

Emyria Limited Announces Commencement of First Dosing for Pivotal EMD-RX5 Phase 3 Trial

Emyria Limited Announces Its Acceptance into the Preclinical Screening Platform for Pain Program

Less than half of directors are independent

Emyria Limited and The University of Western Australia Expands Unique MDMA

Emyria Expands Clinical Sites for EMD-RX5 Phase 3 Trial

Emyria Limited, Annual General Meeting, Oct 25, 2022

Full year 2022 earnings released: AU$0.027 loss per share (vs AU$0.022 loss in FY 2021)

Emyria Limited Receives Ethics Approval for Pivotal EMD-RX5 Phase 3 Trial

Emyria Limited Announces Initiation of Human Cell-Line Preclinical Studies to Advance Its Mdma-Inspired Drug Discovery Partnership with the University of Western Australia

Emyria Limited Announces Positive Progress of its Preclinical MDMA Analogue Medicine Program

Emyria Limited Reports Positive Phase 1 Trial Data for EMD-RX5 Indicating Ideal Bioavailability, Safety and Tolerability Among 12 Healthy and Demographically Diverse Volunteer Subjects

Emyria Limited Receives Further Positive MDMA Analogue Screening Results

Less than half of directors are independent

Emyria Limited Announces EMD-RX5 Dosing to Complete for Phase 1 Clinical Trial

Emyria Limited Commences Dosing for EMD-RX5 Phase 1 Human Clinical Trial

Emyria Limited Commences for the EMD-RX5 Clinical Development Program

Emyria Limited Ethics Approval Receives for EMD-RX5 Phase 1 Study

Emyria Limited Announces Substantial Expansion of Proprietary MDMA Analogue Library Being Created with the University of Western Australia

Emyria Limited Announces Phase 1 Clinical Trials to Commence for Its Leading Ultra-Pure CBD Drug Candidate, Referred to as EMD-RX5

Emyria Limited announced that it expects to receive AUD 5 million in funding from Tattarang Pty Ltd

Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.03 loss in FY 2020)

Emyria Limited Provides Novel Mdma Analogue Screening Program Advanced Update

Full year 2021 earnings released: AU$0.022 loss per share (vs AU$0.03 loss in FY 2020)

Emyria Executes Pure CBD Agreement with Altasciences to Accelerate FDA and TGA Cannabinoid Registration Programs

Emyria Advances EMD-004 Program Towards Registration

Emyria Limited and Mind Medicine Australia Launch MDMA-Assisted Therapy Program for PTSD

First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.016 loss in 1H 2020)

Emyria Limited Announces the Appointment of Dr. Karen Smith to Chair the Company's Strategic Advisory Board

New 90-day high: AU$0.23

Emyria Limited Wins Digital Health Monitoring Grant with UWA

Emyria Limited Appoints Dr Richard Magtengaard, to Its Medical Advisory Board

Emyria Limited to Pursue Registration of EMD-003 with Australia's Therapeutic Goods Administration in 2021

Emyria Limited has completed a Follow-on Equity Offering in the amount of AUD 1.2 million.

Emyria Limited Launches Drug Development Program Based on RWE

Emyria Limited Partners with Mind Medicine Australia

Executive Chairman recently bought AU$61k worth of stock

Emyria Limited Enters Data Deal with Zelira to Support Autism Trial

Zelira Therapeutics Ltd Enters into Agreement with Emyria Ltd

Emerald Clinics Limited to Report Fiscal Year 2020 Results on Oct 30, 2020

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd